Reducing readmissions hasn’t increased post-discharge mortality

Researchers found no evidence that efforts to drop hospital readmissions rates have increased the risk of recently discharged patients dying—in fact, those efforts seem to have reduced post-hospitalization mortality.

The study, published in JAMA, was summarized in a NPR article by study authors Yale School of Medicine professors Kumar Dharmarajan, MD, MBA, and Harlan Krumholz, MD.

“These better outcomes came about not from new medicines or devices, but from a willingness of hospitals and health care professionals to engage with patients and families to promote truly patient-centered, high-quality care,” they wrote. “The idea was to stop focusing on the venue of care and instead recognize the journeys patients are on, and also to stop paying for bad outcomes and instead reward improvements in care. Finally, there was a need recognize that we in health care were not doing as well as we could.”

Read the full article at the link below:

""
John Gregory, Senior Writer

John joined TriMed in 2016, focusing on healthcare policy and regulation. After graduating from Columbia College Chicago, he worked at FM News Chicago and Rivet News Radio, and worked on the state government and politics beat for the Illinois Radio Network. Outside of work, you may find him adding to his never-ending graphic novel collection.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.